BR112016007062A2 - variantes de protoxina-ii e métodos de uso - Google Patents

variantes de protoxina-ii e métodos de uso

Info

Publication number
BR112016007062A2
BR112016007062A2 BR112016007062A BR112016007062A BR112016007062A2 BR 112016007062 A2 BR112016007062 A2 BR 112016007062A2 BR 112016007062 A BR112016007062 A BR 112016007062A BR 112016007062 A BR112016007062 A BR 112016007062A BR 112016007062 A2 BR112016007062 A2 BR 112016007062A2
Authority
BR
Brazil
Prior art keywords
protoxin
variants
methods
preparing
relates
Prior art date
Application number
BR112016007062A
Other languages
English (en)
Inventor
Wickenden Alan
Flinspach Mack
Xue Qinghao
Hagan Rebecca
Neff Robert
Fellows Ross
Liu Yi
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112016007062A2 publication Critical patent/BR112016007062A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

a presente invenção refere-se a variantes de protoxina-ii, polinucleotídeos que codificam as mesmas e métodos de preparo e uso dos mesmos.
BR112016007062A 2013-10-03 2014-10-03 variantes de protoxina-ii e métodos de uso BR112016007062A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361886100P 2013-10-03 2013-10-03
PCT/US2014/058972 WO2015051216A1 (en) 2013-10-03 2014-10-03 Protoxin-ii variants and methods of use

Publications (1)

Publication Number Publication Date
BR112016007062A2 true BR112016007062A2 (pt) 2017-09-12

Family

ID=51830620

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007062A BR112016007062A2 (pt) 2013-10-03 2014-10-03 variantes de protoxina-ii e métodos de uso

Country Status (13)

Country Link
US (2) US9624280B2 (pt)
EP (2) EP3825323A1 (pt)
JP (3) JP6676523B2 (pt)
KR (1) KR20160064192A (pt)
CN (1) CN105793277B (pt)
AU (1) AU2014329454B2 (pt)
BR (1) BR112016007062A2 (pt)
CA (1) CA2926052A1 (pt)
ES (1) ES2841173T3 (pt)
HK (1) HK1224307A1 (pt)
MX (1) MX2016004282A (pt)
PH (1) PH12016500598A1 (pt)
WO (1) WO2015051216A1 (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975129B2 (en) 2013-10-03 2021-04-13 Janssen Biotech, Inc. Protoxin-II variants and methods of use
US10995125B2 (en) 2015-03-03 2021-05-04 Janssen Biotech, Inc. Protoxin-II variants and methods of use
US11083776B2 (en) 2015-04-02 2021-08-10 Janssen Biotech, Inc. Protoxin-II variants and methods of use

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
CA3029132A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
EP3481857A1 (en) 2016-07-06 2019-05-15 Crispr Therapeutics AG Materials and methods for treatment of pain related disorders
EP3568411B1 (en) * 2017-01-13 2024-03-06 Pietro P. Sanna Methods and compositions for treating hpa hyperactivity
WO2024011119A2 (en) * 2022-07-06 2024-01-11 The Regents Of The University Of California Peptides targeting sodium channels to treat pain

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
ATE522598T1 (de) 1997-04-16 2011-09-15 Unigene Lab Inc Direkte expression von peptiden in nährmedien
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
ATE462004T1 (de) 1997-09-16 2010-04-15 Centocor Inc Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen
US20030148273A1 (en) 2000-08-26 2003-08-07 Shoulian Dong Target enrichment and amplification
EP1348466A3 (en) 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Method for treating pain with adenosine-tetraphosphates
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
CA2626584A1 (en) 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
CN101600731A (zh) 2006-09-08 2009-12-09 梅约医学教育与研究基金会 不具备血管舒张活性的促排水和利尿钠多肽
US7998980B2 (en) 2006-09-15 2011-08-16 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
AR063384A1 (es) 2006-10-25 2009-01-28 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
CA2739416C (en) 2008-09-03 2017-10-31 Arbor Vita Corporation Agents and methods for treatment of pain
JPWO2010104115A1 (ja) 2009-03-10 2012-09-13 独立行政法人産業技術総合研究所 膜タンパク質を特異的に認識するポリペプチドの調製方法
JP5555891B2 (ja) 2009-09-15 2014-07-23 アロモネ プリクリニカル リミテッド クモ毒から単離した新規ペプチド及びその使用
EP2545189B1 (en) 2010-03-08 2018-01-10 Dana-Farber Cancer Institute, Inc. Full cold-pcr enrichment with reference blocking sequence
WO2012004664A2 (en) * 2010-07-07 2012-01-12 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
CN101979411A (zh) 2010-10-21 2011-02-23 湖南师范大学 虎纹捕鸟蛛蛋白酶抑制剂
KR20140009311A (ko) 2011-01-18 2014-01-22 암젠 인크 Nav1.7 넉아웃 마우스 및 이의 용도
AU2012250516B2 (en) 2011-05-04 2017-08-31 Aegea Biotechnologies Methods for detecting nucleic acid sequence variants
US9102751B2 (en) 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
CN104768568A (zh) 2012-05-18 2015-07-08 詹森生物科技公司 虎纹捕鸟蛛毒素-iv变体及其使用方法
US9718865B2 (en) 2012-07-27 2017-08-01 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
CN104065367B (zh) 2013-03-20 2017-11-07 江苏多维科技有限公司 一种低功耗磁电阻开关传感器
CN105793277B (zh) 2013-10-03 2020-09-15 詹森生物科技公司 原毒素-ii变体及其使用方法
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
JP6985151B2 (ja) 2015-04-02 2021-12-22 ヤンセン バイオテツク，インコーポレーテツド プロトキシン−ｉｉ変異体及びその使用方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975129B2 (en) 2013-10-03 2021-04-13 Janssen Biotech, Inc. Protoxin-II variants and methods of use
US10995125B2 (en) 2015-03-03 2021-05-04 Janssen Biotech, Inc. Protoxin-II variants and methods of use
US11083776B2 (en) 2015-04-02 2021-08-10 Janssen Biotech, Inc. Protoxin-II variants and methods of use

Also Published As

Publication number Publication date
KR20160064192A (ko) 2016-06-07
JP2016533710A (ja) 2016-11-04
AU2014329454B2 (en) 2019-01-17
US20150099705A1 (en) 2015-04-09
CN105793277A (zh) 2016-07-20
EP3052519A1 (en) 2016-08-10
US20200048316A1 (en) 2020-02-13
JP6676523B2 (ja) 2020-04-08
US10975129B2 (en) 2021-04-13
JP6940636B2 (ja) 2021-09-29
ES2841173T3 (es) 2021-07-07
WO2015051216A1 (en) 2015-04-09
AU2014329454A1 (en) 2016-04-21
CN105793277B (zh) 2020-09-15
US9624280B2 (en) 2017-04-18
PH12016500598A1 (en) 2016-06-13
JP2022008319A (ja) 2022-01-13
MX2016004282A (es) 2016-10-12
EP3052519B1 (en) 2020-11-25
CA2926052A1 (en) 2015-04-09
HK1224307A1 (zh) 2017-08-18
JP2020096606A (ja) 2020-06-25
EP3825323A1 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
NI201400125A (es) Antagonistas de st2l y métodos de uso
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
BR112017018834A2 (pt) variantes de protoxina-ii e métodos de uso
BR112016007062A2 (pt) variantes de protoxina-ii e métodos de uso
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
FR3007989B1 (fr) Autoinjecteur.
FR3013601B1 (fr) Autoinjecteur.
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
BR112015023620A2 (pt) preparação de malto-oligossacarídeos.
IN2013DE00266A (pt)
AR097668A1 (es) Colorante-polímero
BR112015025165A2 (pt) veículo
BR112016007635A2 (pt) inibidores de nsp4 e métodos de uso
BR112016008035A2 (pt) composição, uso da composição
ES2717689T8 (es) Cilindro de cierre
BR112017009302A2 (pt) uso de d-ribose para aperfeiçoar adaptação a tensão física
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
ITPG20130023U1 (it) Emulatore elettroiniettori carburante
TN2013000364A1 (fr) تصميم جديد لطائرة مدنية ذات مقعد واحد و انظمة سلامة متطورة
TH1601002801A (th) วิธีผลิต 2, 3-บิวเทนไดออล
BR302013006409S1 (pt) Configuração ornamental aplicada em mola.
TH148814B (th) องค์ประกอบสำหรับการยกระดับการป้องกันตัวของผิวหนัง

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]